Ключевые слова:
Parkinson’s disease, autoimmunity, neuroinflammation, microglia, cytokines, blood-brain barrier, genetics, immunotherapyБиблиографические ссылки
Appel, S. H. (2017). Autoimmunity and inflammation in Parkinson’s disease. Trends in Neurosciences, 40(6), 358–370.
Tansey, M. G., & Romero-Ramos, M. (2019). Immune system responses in Parkinson’s disease: Early and dynamic. European Journal of Neuroscience, 49(3), 364–383.
Sulzer, D., & Alcalay, R. N. (2021). T cells in Parkinson’s disease. Nature Reviews Neurology, 17(8), 469–483.
Harms, A. S., Thome, A. D., & Standaert, D. G. (2021). Microglia and neuroinflammation in Parkinson’s disease. Current Opinion in Neurobiology, 67, 221–228.
González, H., Elgueta, D., & Hidalgo, C. (2022). Neuroimmune interactions in Parkinson’s disease. Frontiers in Immunology, 13, 839995.
Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. Lancet, 386(9996), 896–912.
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020). The genetic architecture of Parkinson’s disease. Lancet Neurology, 19(2), 170–178.
Lindestam Arlehamn, C. S., et al. (2020). Alpha-synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nature Communications, 11, 1875.
Fellner, L., et al. (2020). The role of viral infections in Parkinson’s disease. Frontiers in Neurology, 11, 581.
Houser, M. C., & Tansey, M. G. (2017). The gut-brain axis: Is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinson’s Disease, 3, 3.
Sampson, T. R., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 167(6), 1469–1480.
Kustrimovic, N., et al. (2019). Inflammatory cytokines in Parkinson’s disease: Implications for non-motor symptoms. Frontiers in Immunology, 10, 987.
Ouchi, Y., et al. (2020). Microglial activation and dopamine terminal loss in early-stage Parkinson’s disease. Annals of Neurology, 87(2), 247–259.
Gordon, R., et al. (2018). NLRP3 inflammasome activation in Parkinson’s disease. Nature Neuroscience, 21, 1787–1799.
Hirsch, E. C., et al. (2019). Neuroinflammation in Parkinson’s disease. Parkinsonism & Related Disorders, 63, 6–11.
Valera, E., & Masliah, E. (2016). Immunotherapeutic approaches for Parkinson disease. Nature Reviews Neurology, 12(11), 387–396.
Bae, E. J., et al. (2018). Anti-inflammatory strategies for Parkinson’s disease therapy. Trends in Pharmacological Sciences, 39(5), 380–396.
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2019). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology, 15(3), 133–150.
Lindqvist, D., et al. (2013). Peripheral inflammation in Parkinson’s disease: A critical review. Acta Neurologica Scandinavica, 127(1), 1–11.
Cao, S., et al. (2021). Crosstalk between systemic immunity and neuroinflammation in Parkinson’s disease. Frontiers in Immunology, 12, 66 2889.